Cargando…
Should ACE2 be given a chance in COVID-19 therapeutics: A semi-systematic review of strategies enhancing ACE2
The severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) has resulted in almost 28 million cases of COVID-19 (Corona virus disease-2019) and more than 900000 deaths worldwide since December 2019. In the absence of effective antiviral therapy and vaccine, treatment of COVID-19 is largely sym...
Autores principales: | Kaur, Upinder, Acharya, Kumudini, Mondal, Ritwick, Singh, Amit, Saso, Luciano, Chakrabarti, Sasanka, Chakrabarti, Sankha Shubhra |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier B.V.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7485553/ https://www.ncbi.nlm.nih.gov/pubmed/32926917 http://dx.doi.org/10.1016/j.ejphar.2020.173545 |
Ejemplares similares
-
Oxidative Stress, Neuroinflammation, and NADPH Oxidase: Implications in the Pathogenesis and Treatment of Alzheimer's Disease
por: Ganguly, Upasana, et al.
Publicado: (2021) -
Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India
por: Chakrabarti, Sasanka, et al.
Publicado: (2022) -
Alpha-synuclein, Proteotoxicity and Parkinson's Disease: Search for Neuroprotective Therapy
por: Ganguly, Upasana, et al.
Publicado: (2018) -
The Pathogenetic Dilemma of Post-COVID-19 Mucormycosis in India
por: Chakrabarti, Sankha Shubhra, et al.
Publicado: (2022) -
Rapidly Progressive Dementia with Asymmetric Rigidity Following ChAdOx1 nCoV-19 Vaccination
por: Chakrabarti, Sankha Shubhra, et al.
Publicado: (2022)